Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19

NCT04496141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-02-28

No results posted yet for this study

Summary

Achieved serum samples of persons with or without evidence of COVID-19 infection are tested using the different commercial SARS-CoV-2 antibody immunoassays. The performance of the immunoassays is then assessed by comparing the 2 groups of samples.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

SARS-CoV-2 antibody immunoassays

Different commercial SARS-CoV-2 antibody immunoassays

Sponsors & Collaborators

  • Hong Kong Sanatorium & Hospital

    lead INDUSTRY

Principal Investigators

  • Jonpaul Sze Tsing Zee, MBChB · Hong Kong Sanatorium & Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04496141 on ClinicalTrials.gov